oasis peptides retatrutide 20 mg | 99%+ Purity | Third-Party Tested | Ships in 24h A multidimensional GLP-3 Reta for Metabolic Research

Medication history: prior GLP-1, tirzepatide, insulin, or sulfonylurea use

Dulaglutide Dulaglutide (Trulicity) is administered subcutaneously at a maximum dose of 1.5 mg once weekly, and available on license since 2014 for people with T2D as monotherapy in those who cannot take metformin or as add-on treatment in people using oral agents and/or insulin

Cui J, Shang A, Wang W, Chen W

Metabolic disorders have become more severe due to dietary changes, lifestyle changes, and growing urbanization, which have increased demand for novel treatments like GLP-1 analogues

It also has a longer track record, gastric sleeve and gastric bypass outcomes have been studied for decades

(1982) 24:III-XI, 188:III-88